IDT Biologika Capabilities Update May 2026: Mammalian Cell Culture

This webinar provides an expert overview of how IDT Biologika leverages advanced mammalian cell culture platforms to enable efficient, scalable biopharmaceutical development and manufacturing. You will gain insights into our state-of-the-art technologies, optimized process strategies, and end-to-end service capabilities that accelerate time to clinic and ensure high quality biologics production.

IDT Biologika, as part of SK bioscience, is a globally operating contract development and manufacturing organization (CDMO) specializing in end-to-end services for cell culture and microbial-based proteins, monoclonal antibodies, vaccines, gene and immune therapeutics, biosimilars and other sterile injectables.

With more than 100 years of expertise in biopharmaceutical manufacturing, we support our clients in process & analytical development, drug substance manufacturing, fill-finish, secondary packaging and quality control & analytics. We deliver GMP solutions that combine flexibility, quality, and full regulatory compliance, including FDA, EMA and ANVISA approval.

Levering deep biopharmaceutical manufacturing expertise and proprietary technologies, such as own cell lines, together with highly experienced teams, we enable smooth process & analytical development, technology transfer, scale-up and manufacturing readiness.